Truist Financial Maintains Compugen(CGEN.US) With Buy Rating
Stifel Maintains Compugen(CGEN.US) With Buy Rating, Maintains Target Price $4
Compugen (CGEN) Receives a Buy From Stifel Nicolaus
Truist Financial Maintains Compugen(CGEN.US) With Buy Rating
Stifel Maintains Compugen(CGEN.US) With Buy Rating, Maintains Target Price $4
Stifel Nicolaus Keeps Their Buy Rating on Compugen (CGEN)
Compugen's Strategic Shift to PROC Program Merits a Buy Rating
Truist Securities: Maintaining Compugen's (CGEN.US) rating, adjusted from buy to buy rating, and adjusted target price from $5.00 to $4.00.
Compugen Analyst Ratings
Truist Securities Maintains Buy on Compugen, Lowers Price Target to $4
Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating
Truist Financial Reaffirms Their Buy Rating on Compugen (CGEN)
Compugen Analyst Ratings
Truist Securities Maintains Buy on Compugen, Raises Price Target to $5
Analysts Offer Insights on Healthcare Companies: Cigna (CI), Compugen (CGEN) and OrthoPediatrics (KIDS)
Buy Rating Justified by Compugen's Positive Clinical Outlook and Financial Stability
Compugen (CGEN) Receives a Buy From Stifel Nicolaus
Stifel Maintains Buy on Compugen, Raises Price Target to $4
Compugen Analyst Ratings
Truist Securities Reiterates Buy on Compugen, Maintains $4 Price Target